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Abstract
Background: Follicular lymphoma (FL) is a form of non-Hodgkin’s lymphoma (NHL) that arises from germinal center (GC) B-
cells. Despite the significant advances in immunotherapy, FL is still not curable. Beyond transcriptional profiling and
genomics datasets, there currently is no epigenome-scale dataset or integrative biology approach that can adequately
model this disease and therefore identify novel mechanisms and targets for successful prevention and treatment of FL.
Methodology/Principal Findings: We performed methylation-enriched genome-wide bisulfite sequencing of FL cells and
normal CD19+ B-cells using 454 sequencing technology. The methylated DNA fragments were enriched with methyl-binding
proteins, treated with bisulfite, and sequenced using the Roche-454 GS FLX sequencer. The total number of bases covered
in the human genome was 18.2 and 49.3 million including 726,003 and 1.3 million CpGs in FL and CD19+ B-cells,
respectively. 11,971 and 7,882 methylated regions of interest (MRIs) were identified respectively. The genome-wide
distribution of these MRIs displayed significant differences between FL and normal B-cells. A reverse trend in the
distribution of MRIs between the promoter and the gene body was observed in FL and CD19+ B-cells. The MRIs identified in
FL cells also correlated well with transcriptomic data and ChIP-on-Chip analyses of genome-wide histone modifications such
as tri-methyl-H3K27, and tri-methyl-H3K4, indicating a concerted epigenetic alteration in FL cells.
Conclusions/Significance: This study is the first to provide a large scale and comprehensive analysis of the DNA methylation
sequence composition and distribution in the FL epigenome. These integrated approaches have led to the discovery of
novel and frequent targets of aberrant epigenetic alterations. The genome-wide bisulfite sequencing approach developed
here can be a useful tool for profiling DNA methylation in clinical samples.
Citation: Choi J-H, Li Y, Guo J, Pei L, Rauch TA, et al. (2010) Genome-Wide DNA Methylation Maps in Follicular Lymphoma Cells Determined by Methylation-
Enriched Bisulfite Sequencing. PLoS ONE 5(9): e13020. doi:10.1371/journal.pone.0013020
Editor: Patrick Tan, Duke-National University of Singapore Graduate Medical School, Singapore
Received February 6, 2010; Accepted August 21, 2010; Published September 29, 2010
Copyright:  2010 Choi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by National Cancer Institute grants CA123018, CA123565, CA 132706, DA025779 (H. S.) and Department of Defense grant
W81XWH-07-1-0560 (D. X. and H.S.). H. S. is a Georgia Cancer Coalition Distinguished Cancer Scientist. C. W. C. is CRC Missouri Chair in Cancer Research. R. S. K. was
supported by an NIH Biomedical and Health Informatics Research Training Program (LM07089). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: hshi@mcg.edu
. These authors contributed equally to this work.
Introduction
Twomajor processes that contribute to the epigenome of a cell are
DNAmethylation and histone modifications.Methylation of cytosine
residues at CpG dinucleotides is known to regulate gene expression
and aberrant promoter hypermethylation has been associated with
transcriptional silencing of tumor suppressor genes (TSGs) in various
types of tumors including hematological malignancies [1,2]. Given
the important role of DNA methylation in tumor initiation and
progression, distinct efforts have been made towards the use of DNA
methylation as a biomarker in cancer [3,4]. In addition, since this
epigenetic change potentially is reversible, demethylating agents now
are approved for use in the treatment of hematological tumors such
as myelodysplastic syndrome [5]. Although lymphomas and
leukemias are well characterized by widespread genomic abnormal-
ities such as chromosome translocations, we and others have found
that aberrant promoter hypermethylation also is a common event in
hematological tumors [6,7,8,9,10].
Polycomb (PcG) proteins are multiprotein complexes that
epigenetically silence gene expression, including many TSGs
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[11]. PcG proteins exist in at least two separate protein complexes:
Polycomb repressive complex 1 & 2 (PRC1 and PRC2). PRC2,
consisting of EED, EZH2, YY1 and SUZ12, is thought to be
required at the initiating stage of silencing, whereas PRC1,
containing HPH, RING1,BMI1, and HPC, is required continu-
ously for the stable maintenance of the initiated PcG repression on
specific target loci [12]. EZH2 has histone methyltransferase
activity specific for histone H3 lysine 27, and SUZ12 and EED are
required for this activity. EZH2 can directly recruit DNA
methyltransferases (DNMTs) and lead to de novo DNA methylation
[13]. EZH2 is known to play an important role in B-cell
development and VDJ recombination [14]. Further immunohis-
tochemical studies have revealed that in the germinal center,
proliferating centroblasts express certain components of the PRC2
complex, whereas non-proliferating centrocytes and naı¨ve B cells
do not [15]. Recent studies have shown that a large group of
frequently methylated genes in FL cells were targets of the PRC2
complex in embryonic stem (ES) cells [6,8,10]. Although the
underlying mechanism is still unclear, dysregulation of polycomb
protein expression was reported in lymphomas [15,16]. It is
postulated that germinal center lymphomas such as FL are
initiated in the germinal center stage with proliferating cells and
elevated polycomb protein expression [7].
In this study, we have integrated the concept of reduced
representation bisulfite sequencing (RRBS) with the methylated
CGI recovery assay (MIRA) for genome-wide bisulfite sequencing
analysis using 454-sequencing technology. We have sequenced the
methylome of a FL cell line and normal CD19+ B-cells. We also
compared the genome-wide methylation patterns with gene
expression and histone methylation profiles in FL cells. These
integrated analyses identified many novel DNA methylation
targets in the FL epigenome and provided a comprehensive
analysis of the DNA methylation present within the genome and
the distribution of other epigenetic marks.
Results
Genome-wide bisulfite sequencing of RL and CD19+
B-cell DNA
Using the bisulfite sequencing strategy illustrated in Figure 1A–
B and described in detail in the methods section, we first
sequenced the FL cell line, RL. We collected 518,797 bisulfite
sequences (approximately 100 Mb) with an average read length of
143 bp after trimming off the adaptor sequences (range 20 bp to
444 bp, see Figure 1C) using the GS FLX sequencer. A novel
program called BSmapper was used to align bisulfite sequences to
the human genome. After filtering out the sequences mapped to
short clusters of length less than 50 bp, 389,038 bisulfite sequences
(75% of all reads) were uniquely mapped to the non-repeat-
masked human genome (NCBI build 36.1,hg18). Overall 101,631
unique genomic loci were mapped by at least one sequence read
and the total number of bases covered in the human genome by all
sequencing reads was approximately 18.2 million including 5.3
million cytosines and 726,003 CpGs (Table 1). 78.5% of the
726,003 CpGs sequences contain methylated cytosines. Bisulfite
treatment efficiency was determined by calculating the C to T
conversion rate for all cytosine bases other than those in CpG
dinucleotides (this includes CpA, CpC or CpT dinucleotides and is
from this point referred to as CpH). The bisulfite conversion rate
was estimated to be 97%, however, it could not be determined if
any of the unconverted cytosines were due to de novo CpH
methylation. Similar to the ChIP-seq method [17], since methyl-
binding proteins were used to extract the methylated GC-rich
DNA, we observed significant enrichment of sequence reads at
CGI regions compared to other genomic regions. Using
chromosome 7 as an example (Figure 1D), the alignment results
show that the peak of the sequence reads mapped to the genome
correlated well with the distribution of CGIs along the
chromosome.
We also generated 403,525 bisulfite sequences (approximately
88 Mb) for CD19+ B-cells isolated from normal peripheral blood
using the GS FLX sequencer, but with the new Titanium
chemistry. The average read length was 218 bp after trimming
off the adaptor sequences (range 20 to 692 bp). The longer
average read length was mainly due to the improved sequencing
chemistry. 351,015 bisulfite sequences (83% of all reads) were
uniquely mapped (Table 1). The total number of bases covered in
the genome was 49.3 million including 12.3 million cytosines and
1.3 million CpGs (Table 1). Nearly 90% of the 1.3 million CpGs
contain methylated cytosines. Although the total number of reads
uniquely mapped to the genome was similar between RL and
CD19+ B-cells, the total number of bases or CpGs covered in the
genome was significantly higher for CD19+ B-cells. The genomic
loci identified were nearly doubled for CD19+ B-cells.
Distribution of methylated DNA across the genome in RL
and CD19+ B-cells
As a majority of the genomic loci were mapped with fewer reads
(Figure 2A), we established a threshold for identifying clustered
regions with multiple overlapping or continuous sequencing reads
($5) and longer than 50 bp. Using this criteria, we identified
13,082 and 8,020 clusters in RL and CD19+ B-cells, respectively
(Table 1). The average number of reads per cluster was 19.5 and
10.3, and the maximum number of reads for a given cluster was
1,969 and 2,395 in RL and CD19+ B-cells, respectively. The
average length of a cluster was 280 bp (range 50 to 2,438 bp) and
402 bp (range 50 to 2,430), respectively. After excluding 318 and
95 clusters in RL and CD19+ B-cells that do not contain any CpG
sites, we calculated the methylation index for each cluster by
averaging the methylation level at each CpG site within each
cluster. Figure 2B shows the distribution of methylation indices of
CpGs among clusters, with most being largely methylated (.80%).
However, 793 and 43 clusters were identified with a DNA
methylation index of less than or equal to 20% in RL and CD19+
B-cells, respectively.
We defined a methylated region of interest (MRI) if a particular
cluster was at least 50 bp long, contained at least 5 mappable
reads, and had a methylation index of greater than 20%. Figure S1
shows the distribution of these clusters across the genomes of RL
and CD19+ B-cells. Independent confirmation studies of several
loci using the Sequenom MassArray demonstrated that these
parameters were stringent enough for identifying MRIs. Examples
of the confirmation studies can be found in Figure S2A–D. We
also conducted a permutation test to assess whether the
distribution of methylation levels of MRIs was obtained by chance
in RL cells. For each permutation, we randomly shuffled the
methylation level of all CpGs in our data set, calculated the
average methylation level of clusters, and then determined MRIs.
Figure S3A shows a histogram of methylation indices after 1000
permutations. Compared to Figure 2B left panel, the number of
clusters with 0 or 100% methylation was significantly reduced,
suggesting that it was unlikely to obtain the original distribution by
chance. A student t-test was performed for each permutation to
assess how much a permuted distribution was similar to the
original distribution. Figure S3B shows that all p-values in 1000
permutations were less than 0.003, indicating that the criteria used
to determine MRIs were reasonable.
MIRA Bisulfite Sequencing
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A total of 11,971 and 7,882 MRIs were identified in RL and
CD19+ B-cells based on the parameters mentioned above. Similar
to the previous report [18], the number of MRIs per chromosome
was roughly correlated with the size of the chromosomes in CD19+
B-cells (Figure 2C, right panel). Several chromosomes such as
chromosomes 16, 17, 19, and 22, had a higher number of MRIs
per Mb, and chromosomes X and Y had the lowest number of
MRIs per Mb. However, the distribution of MRIs among
chromosomes was skewed in RL cells. The Pearson’s correlation
coefficient between the number of MRIs and the size of the
chromosomes dropped by nearly half (Figure 2C, left panel). The
number of MRIs on chromosome 13 and 18 dropped more than 2
fold. Rauch et al. (2009) identified more MRIs in normal CD19+ B
cells than our study [18]. This difference primarily was due to the
analytical platforms (microarray vs. sequencing) and the reduced
representation by restriction enzymes employed in our study, but
not in Rauch’s study.
In RL cells, 30% of the 11,971 MRIs were located within or
overlap with 4,033 CGIs, which accounts for 14.3% of all CGIs
annotated in the UCSC genome browser. In general, these MRIs
Figure 1. Experimental Design. A. Schematic diagram of MIRA-454 sequencing approach. B. Left panel: Gel electrophoresis of Mse I (M), Bfa I (B),
and Csp 6I (C) digested genomic DNA. Right panel: PCR results of the adaptor-ligated and bisulfite-treated DNA. C. Histogram of the read length
distribution of bisulfite sequences obtained from 454-sequencing of the methylation enriched genomic library. D. Mapping of the bisulfite
sequencing reads along chromosome 7. A custom track was generated from alignment results of bisulfite sequences on human genome. The track
was uploaded to the UCSC genome browser and compared with other tracks such as RefSeq genes and CpG islands.
doi:10.1371/journal.pone.0013020.g001
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covered four distinct sequence categories based on gene
annotation (NCBI Build 36). As shown in Figure 3A left panel,
2,054 (17.2%) of the 11, 971 MRIs were located within the 59-
end of annotated genes (defined as22,200 bp to +500 bp around
the transcription start sites), 5,557 (or 46.2%) were located in the
gene body (+500 bp to the transcription start and2500 bp to the
transcript end) and 275 (or 2.3%) at the 39-end of a gene
(6500 bp to the transcript end). The list of MRIs located in the
59-end of the genes can be found in Table S1. 4,086 (or 34.1%)
MRIs were located in intergenic regions of the annotated genes.
However, for those MRIs associated with CGIs, nearly half of the
MRIs were located within the 59-end of annotated genes
(Figure 3B left panel). 4,867 (,40%) MRIs mapped to regions
that contain repeat sequences, and the most abundant repeat
sequences were SINEs, simple repeats, LINEs and LTRs
(Figure 3C left panel).
In contrast with RL, only 1,000 (12.3%) of the 7,882 MRIs
identified in CD19+ B-cells were located within or overlap with
CGIs; and only 215 (2.7%) of the 7,882 MRIs were located within
the 59-end of annotated genes (Figure 3A right panel). The list of
MRIs located in the 59-end of the genes in CD19+ B-cells can be
found in Table S2. Most of the MRIs (95%) identified in CD19+
B-cells were located in either intra- or intergenic regions. The
percentage of MRIs located in the 39-end of the annotated genes
were similar between RL and CD19+ B-cells. However, only 11%
of the MRIs associated with CGIs were located at the 59-end of
annotated genes in CD19+ B-cells and two thirds of them were
located within the intragenic regions in CD19+ B-cells (Figure 3B,
right panel). In addition, 60% of MRIs in CD19+ B-cells mapped
to the regions that contain repeat sequences (Figure 3C right
panel).
Overall, the sequencing results indicated that the distribution of
MRIs in RL and normal B-cells was quite different. The MRIs
identified in normal B-cells were mostly in intra- or intergenic
regions and were associated with repetitive sequences. However,
the proportion of MRIs located in the promoter or 59-end of genes
was significantly higher in RL cells, while the number of MRIs
located within intra- or intergenic regions decreased as compared
to CD19+ B-cells. Among 11,971 MRIs identified in RL cells,
1,455 of them overlapped with the 7,882 MRIs identified in
CD19+ B-cells, accounting for only 12% of the MRIs identified in
RL cells. The Pearson’s correlation coefficient between the
methylation levels of MRIs in RL and CD19+ B-cells was also
quite low (Figure S4).
Promoter hypermethylation in RL cells
We identified 1,878 and 223 genes that were associated with
MRIs in the 59-end of these genes in RL and CD19+ B-cells,
respectively (See Table S1 and S2). 59 genes were methylated in
both RL and CD19+ B-cells; 1,817 and 164 genes were only
methylated in either RL or CD19+ B-cells, respectively. Since our
previous study [10] found that a number of hox genes were
methylated in RL cells, we decided to take a look at all of the
HOX gene families in RL and CD19+ B-cells. Figures 4A-B and
S5 show that multiple bisulfite sequencing reads were aligned to
over a dozen HOX genes including HOX A4, A5, A6, A9, A10,
A11, A13, B1, B2, B8, B9, B13, C5, C9, C12, D1, D3, D8 and D13.
We confirmed HOXA4 and HOXA9 promoter CGI methylation
in RL cell line, primary FL, and normal CD19+ B-cells using the
Sequenom MassArray Technology (Figure 4C). The MassArray
data demonstrated that 8 out of 10 HOX A genes were
methylated at intermediate or lower levels in normal peripheral
blood mononuclear cells (PBMCs) and CD19+ B cells isolated
from PBMCs, but become hypermethylated in FL cells
(Figure 4D). Only HOXA3 and HOXA5 showed similar levels of
methylation in FL and normal CD19+ B- cells. Overall,
methylation of the HOXA genes in the primary FL tumor and
the RL cell line were similar. In addition to HOX gene clusters,
we identified methylation in the promoter CGIs of several
protocadherin gene families, all of which are located at
chromosome 5q21 (See Figure S6). The protocadherin gene
family has genomic structure similar to IGH and has multiple
splicing forms and multiple alternative promoters. Our sequenc-
ing data shows that a majority of these promoter CGIs are
methylated in both RL cells and CD19+ B-cells. Most of these
genomic regions span over one hundred thousand to several
million base pairs. Methylation seems to play an important role
in controlling gene expression of large genomic regions, which is
consistent with similar observations from several recent publica-
tions [19,20].
Methylation also was observed in other gene families or
pathways that share similar molecular functions. For example,
methylation was observed in the promoter of 11 out of 20 SOX
genes and 7 out of 10 Frizzled protein genes in RL cells. We
analyzed the 1,817 genes that were hypermethylated only in RL
cells using the DAVID interface (http://david.abcc.ncifcrf.gov/).
Using the functional annotation clustering with high stringency,
these genes fell within 4 major functional groups including
development, glycoproteins, signal transduction, and transcrip-
Table 1. Summary Statistics.
all Mapped with .=5 reads & length .50 bp
RL CD19+ B-Cells RL CD19+ B-Cells
Total number of read 518,797 422,466
Total number of reads uniquely mapped 389,038 351,015 256,430 82,653
Total number of bases covered in the human genome 18,221,899 49,257,534 3,665,341 3,226,745
Maximal, minimal and average mapped read length after
trimming off linker sequences
444/20/156 692/20/218 442/50/158 692/20/228
Total number of cytosines covered in the human genome 5,287,738 12,251,399 1,160,014 895,043
Total number of CpGs covered in the human genome 726,003 1,332,822 227,904 152,846
Total number of mCpGs identified 570,260 1,205,001 198,839 148,205
Total number of genomic loci identified 101,632 207,708 13,082 8,020
Total number of CpG islands sequenced 12,757 4,915 4,479 1,000
doi:10.1371/journal.pone.0013020.t001
MIRA Bisulfite Sequencing
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Figure 2. Distribution of bisulfite sequencing reads in the human genome. A. Identification of clustered bisulfite sequencing reads on each
chromosome. The colors indicate the number of bisulfite sequencing reads mapped to each cluster. Each column indicates the total number of
genomic loci mapped with bisulfite sequences on each chromosome. The color scales indicate the number of reads mapped to each locus. The
number on the top of each column indicates the number of clusters mapped with 10 or more reads on each chromosome. B. The histogram of the
distribution of DNA methylation indices across all clusters mapped with at least 5 sequencing reads. C. Distribution of MRIs along individual
chromosomes. The number of MRIs was plotted against the length of the chromosomes.
doi:10.1371/journal.pone.0013020.g002
MIRA Bisulfite Sequencing
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tional factors (Figure S7). Similar to our previous study using
microarray-based analyses, genes for homeobox proteins and the
WNT signaling pathway were among the most enriched functional
groups [10].
The hypermethylated genes in RL also contained a large
number of known genes found to be methylated in primary FLs
(See Table S1) by previous studies [6,7,8,10]. We now have
detailed DNA methylation maps of these candidate genes in RL.
As an example, DNA methylation patterns of a 200 bp fragment
located in the first exon of tumor suppressor gene HIC-1 is shown
in Figure S8. There seems to be a gradual decrease in methylation
towards the 59end of the gene. The first 50 bp of this 200 bp
fragment contains mostly unmethylated CpGs, while the next
150 bp are predominately methylated. However, this observation
may require further validation. We also observed interesting
methylation patterns in HLA-A, where a heterozygous polymor-
phism (rs41558424) can determine the methylation status of
adjacent CpG sites (Figure S9). The expression of HLA-A genes
also was down regulated in RL cells and can be up-regulated by
demethylating treatments (data not shown).
Figure 3. Distribution of MRIs and methylated CpG islands relative to annotated genes. A. Pie charts of the distribution of MRIs relative to
annotated genes. The MRIs identified in RL and CD19+ B-cells were annotated based on their location with respect to genes as described in the text.
B. Pie charts of the distribution of MRIs associated with CGIs relative to annotated genes. C. Pie charts of the distribution of the repetitive sequences
in MRIs identified in RL and CD19+ B-cells.
doi:10.1371/journal.pone.0013020.g003
MIRA Bisulfite Sequencing
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Figure 4. Bisulfite sequencing results of the HOX A gene cluster. A. Alignment results of bisulfite sequencing reads in the HOX A gene cluster
are shown as custom tracks in UCSC genome browser. The top two tracks show CpG sites that are covered by sequencing reads. The red bars indicate
methylated CpGs. The middle two tracks in blue color indicate the coverage of sequencing reads at each CpG site. B. A blow-out view of two loci
(HOXA4 and HOXA9) mapped with multiple bisulfite sequencing reads were shown in the lower panel. The vertical bar in red color indicates the level
of methylation at each CpG site. The deeper red shade indicates the higher methylation level. The horizontal tracks in pink color are the individual
bisulfite sequencing reads. C. The bisulfite PCR products corresponding to the two regions in panel B were analyzed using the MassArray method.
Bisulfite- treated genomic DNA from normal PBMC, CD19+ B-cell, a FL patient sample and RL was used as template for PCR. Each circle indicates a CpG
MIRA Bisulfite Sequencing
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Correlation of DNA methylation with other epigenetic
modifications in RL cells
Recent studies from our own group and others show that
methylated genes identified in FL significantly overlap with PRC2
target genes in ES cells [6,8,10]. We therefore queried the list of
genes associated with MRIs in the promoter region using
ONCOMINE concept map analysis and the results confirmed
that the methylated genes identified by 454-sequencing in RL cells
significantly overlap the PRC2 target genes in ES cells (Figure
S10). To investigate the correlation of DNA methylation with
other epigenetic marks we generated genome-wide profiles of
histone H3 lysine 4 tri-methylation (H3K4Me3), H3 lysine 27 tri-
methylation (H3K27Me3), and SUZ12 binding in RL cells using
ChIP-on-Chip assays on the NimbleGen 385K minimal promoter
array. This array is designed to interrogate promoter regions, at
positions 22,200 bp to +500 bp around the transcription start
sites. The ChIP-on-Chip analyses revealed that 5,068 promoters
were enriched with H3K4Me3 in RL cells; 2,117 of promoters
were enriched with H3K27Me3, and 548 promoters were bound
by Suz12 (Table S3, S4, S5). The ChIP-on-Chip results were
confirmed independently using ChIP-PCR (Figure S11). The
global analyses showed that MRIs do not overlap significantly with
either H3K4 or H3K27 tri-methylation in the promoter regions in
RL cells (Figure 5A left panel). In contrast to ES cells, we found
only 99 bivalent promoters in RL cells and 11 of them co-localize
with MRIs. Although 28% of MRIs are PRC2 target genes in ES
cells, our ChIP-on-Chip analysis showed that only 13% of MRIs
are associated with H3K27Me3 marks and only 5% of the MRIs
are bound by Suz12 in RL cells in vivo (Figure 5A right panel).
Figure 5B shows several examples of the complexity of gene
specific epigenetic regulation. SUZ12 binding, histone H3K27
trimethylation and DNA methylation co-localized in the LHX6
promoter, while SOX1 seems to be silenced only by promoter
DNA methylation. NOTCH2, which plays a pivotal role in the
development of marginal zone B-cells, had a bivalent promoter.
The promoter of the c-MYC oncogene was completely occupied by
histone H3K4 trimethylation. Gene-ontology analysis showed that
H3K27Me3 and SUZ12 regulated a different set of genes in RL
cells compared to ES cells. Expression of many lineage specific
genes seemed to be controlled by histone modifications. For
instance, H3K27Me3 marks were associated with CD34 and
CD44 in RL cells, while H3K4Me3 marks were associated with
CD19, CD10 (MME), CD27 and CD38.
Correlation of DNA methylation with gene expression
profiles
We compared the DNA methylation, histone methylation and
previously published gene expression profiles obtained from the
RL cell line [10]. mRNA expression analyses of RL cells treated
with the demethylating agent, 59-aza-29-deoxycytidine (DAC) and
the histone deacetylase (HDAC) inhibitors, Trichostatin A (TSA),
and normal CD19+ B cells from tonsil and PBMCs were
conducted using Illumina whole genome bead arrays [10]. 1,831
of the 25,400 RefSeq genes have MRIs mapped in the promoter
or 59 regulatory regions. In general, the expression of these genes
was correlated with level of DNA methylation of MRIs (Figure 6A
left panel). The median value of absolute gene expression was
much higher for the genes with lower DNA methylation levels.
4,510 and 1,935 genes had H3K4Me3 and H3K27Me3 marks
enriched in their promoter, respectively and the gene expression
levels also correlated well with histone modifications overall. The
genes associated with promoter H3K4Me3 methylation displayed
higher median expression levels even if DNA methylation or
H3K27Me3 marks co-existed. On the contrary, genes associated
with promoter DNA methylation or H3K27Me3 alone and in
combination had lower median expression levels (Figure 6A
middle panel). Expression array analyses also revealed that a group
of genes that were down regulated in RL cells could be reactivated
by epigenetic drug treatments (Figure 6A right panel). Interestingly
IRF4, a tumor suppressor gene in lymphoma and a repressor of
BCL6 transcription was methylated in RL cells (Figure 6B) and
down regulated in RL cells (Figure 6C left panel) and primary FL
cells (Figure 6C right panel). IRF4 could be reactivated by DAC
and co-treatment with TSA, suggesting to a synergistic reactiva-
tion effect (Figure 6C left panel). Further analysis using COBRA
showed that methylation in the same locus was identified in
primary FL and diffuse large B cell lymphoma (DLBCL) patients’
DNA samples, but not in follicular hyperplasia (FH) and normal
control male and female (PBMCs) DNA (Figure 6D).
Discussion
The power of next-generation DNA sequencing technology
such as, Roche/454 GS FLX, Illumina Genome Analyzer and
ABI SOLiD, is transforming the landscape of epigenomic
research. New epigenomic applications such as ChIP-Seq and
genome-wide bisulfite sequencing (BS-Seq) have emerged. We
previously performed ultra-deep sequencing analysis of bisulfite-
modified lymphoma DNA using 454-sequencing [21]. Since then,
bisulfite treatment and high-throughput massively parallel se-
quencing has been used successfully to map a complete methylome
of Arabidopsis [22,23] and most recently the methylome of two
human cell lines [24]. Although nearly complete sequencing of the
methylome of human cells was an outstanding achievement, the
whole-genome shotgun approach is too costly to be applied to
analyze multiple disease related samples. Meissner et al. described
a large-scale random approach termed reduced representation
bisulfite sequencing (RRBS) for analyzing and comparing genomic
methylation patterns using Illumia/Solexa sequencing [25]. This
approach used a restriction enzyme and a size selection step to
generate and sequence a defined fraction of a large genome.
Zeschnigk et al. applied a similar approach using 454-sequencing
with a combination of 4 different restriction enzymes [26]. Several
other groups have also developed methods for targeted genome-
level bisulfite sequencing [27,28,29]. However, these approaches
are quite complicated and can achieve substantially lower genomic
coverage, making these technologies more suitable for validating
findings than for initial discovery [30].
In this study, we described a simple method for the selective
sequencing of methylated DNA using next generation sequencing
instruments. Using MIRA coupled with 454 sequencing, we
demonstrated a highly efficient capture of methylated DNA
followed by in-depth sequencing of a large number of CpG islands.
The longer bisulfite sequences obtained by 454-sequencing made
sequence alignment more accurate and reliable. Above 75% of the
bisulfite sequence reads were uniquely mapped and produced
meaningful methylation data. This mapping rate of bisulfite
site and the methylation level is indicated by color. The methylation level was determined as an average of four independent replicates. D. MassArray
analysis of 10 HOXA genes is shown as Bar graph. Each bar represents the average methylation level of all CpG sites analyzed by each bisulfite PCR
product. Error bar are generate from 4 replicates.
doi:10.1371/journal.pone.0013020.g004
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Figure 5. Correlation of DNA methylation with histone methylation and transcriptional repressor binding. A. Venn diagrams showing
an overlap of MRIs with genes associated with H3K4Me3 and H3K27Me3 marks (left) and an overlap of MRIs with SUZ12 target genes in ES cells and
RL cells (right). B. DNA methylation, H3K4Me3, H3K27Me3, and SUZ12 binding profiles in four representative promoters including LHX6 (top left),
NOTCH2 (top right), SOX1 (bottom left), and c-MYC (bottom right). Each blue bar corresponds to the log2 ratio of ChIP/Input DNA for an individual
probe. The methylation tracks are the same as described in Figure 4.
doi:10.1371/journal.pone.0013020.g005
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Figure 6. DNA methylation and gene expression. A. Box plot showing median expression values of genes associated with MRIs correlate with
degree of methylation (left), the histone methylation marks (middle), and genes associated with MRIs that were down-regulated in RL cells could be
re-activated upon treatment of DAC or DAC plus TSA(right). The y-axis shows the log10 transformed arbitrary expression value for each individual
probe that represents the corresponding transcript. We performed pair wise t-test on the data shown in all three panels and the results can be found
in Table S6. Most of the p-values were quite small and demonstrate the differences between groups were significant. B. Alignment of bisulfite
sequencing reads at 59 end of IRF4. The vertical line in red color indicates the level of methylation at each CpG site, which is the same as described
above. The horizontal tracks in pink color are the individual bisulfite sequencing reads. C. mRNA expression analysis by microarray shows that IRF4 is
down-regulated in RL cells and can be reactivated by DAC and DAC plus TSA treatment (left). The right panel shows IRF4 expression in normal lymph
nodes (blue) and follicular lymphoma (red), as reported in ref [42]. D. COBRA analysis of IRF4 methylation in primary FL, DLBCL, FH and normal control
DNA. Symbols: C, untreated RL control; A, RL with DAC; AT, RL with DAC plus TSA; To, tonsil CD19+ B-cells; PBL, CD19 B-cells isolated from PBMC; LN:
lymph node; FH, follicular hyperplasia.
doi:10.1371/journal.pone.0013020.g006
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sequences was significantly higher than those obtained by Illumina
short read sequencing platform, which usually varies significantly
between samples [30]. Although the approach we used was biased
toward methylated GC-rich DNA sequences, interesting DNA
methylation patterns were discovered. For instance, a heterozy-
gous polymorphism (rs41558424), located within a CpG island in
the HLA-A gene cluster, was correlated with the methylation
status of two neighboring CpG sites (Figure S9). This interesting
methylation pattern obtained in the HLA-A region demonstrated
that read length matters. Although the bisulfite sequencing results
obtained by short read sequencing can adequately quantify the
methylation levels, they will not provide single molecule
methylation patterns. The methylation patterns observed in
Supporting Figure S8 and S9 might not be revealed clearly if
short read sequencing were performed.
For the first time, we generated genome-wide, single base-pair
resolution DNA methylation maps in FL and CD19+ B-cells.
These epigenetic ‘‘maps’’ should facilitate a greater understanding
of the role of epigenetic modifications in FL. Our results
demonstrate that DNA methylation changes in FL are profound
and support the notation that aberrant methylation pattern in
tumors consists of a global hypomethylation, in conjunction with
localized hypermethylation in CpG islands [2]. Recent studies also
show that gene body methylation is associated with active gene
expression [27]. Interestingly, for those methylated CGIs, we
observed a reverse trend between promoter and gene-body
methylation in RL and CD19+ B-cells. Significantly more (2054
vs. 215) MRIs were identified in the promoter and 59-end of genes
in the FL cell line compared to CD19+ B-cells, suggesting a strong
shift towards gains in hypermethylation of promoter CGIs in FL
cells. The sequencing results also showed that most of the MRIs
identified in CD19+ B-cells were located in the intra- and
intergenic regions and were associated with repetitive sequences.
Particularly, over two thirds of methylated CGIs in CD19+ B-cells
were located in the gene body. These numbers decreased in the FL
cells, suggesting hypomethylation in the intra- and intergenic
regions. Although these findings are not completely novel, this is
the first time that these phenomena are examined in such a large
scale and at a single molecule level in FL cells.
Previously, we have found a large number of methylated genes
in RL cells as well as primary FL patient samples using
microarray approaches [9,10,31], which suggest that RL is a
good in vitro model for studying DNA methylation in FL. Using
the massively parallel bisulfite sequencing approach, we
confirmed a large number of methylated genes in RL cells,
and identified distinguishing methylation patterns in the
promoters of these genes. Gene specific methylation patterns
for many tumor suppressor genes such as HIC-1, CDKN1C (p57),
and IRF4 were established. Interestingly, IRF4 is a tumor
suppressor gene in lymphoma and functions as a suppressor of
BCL6 transcription [32]. Our data suggest that hypermethyla-
tion of the IRF4 gene might be one of the epigenetic mechanisms
of IRF4 down-regulation, which could then lead to BCL6 over-
expression. We also established the DNAmethylation patterns of
HOX gene clusters. The MassArray data further confirmed the
increased methylation in RL cells and primary FL patient
samples compared to normal B- cells, suggesting that hyper-
methylation of HOX genes was tumor specific. The functional
consequences of hypermethylation in these HOX genes are
largely unknown and further investigation into the extent of
aberrant methylation in HOX gene clusters in primary FLs will
be very interesting. The large data set generated in this study can
become a great resource for future studies of these candidate
genes. Our data can serve as a guide for the identification of
specific methylated regions of interest and design of gene-
specific methylation assays.
Previous studies showed that a large number of PRC2 target
genes were hypermethylated in FL cells [6,8,10]. However,
combined with the ChIP-on-Chip analysis, we found that only a
fraction of those target genes were bound by SUZ12, one of the
major components of the PRC2 complex. We chose SUZ12
instead of EZH2 for the ChIP-on-Chip analysis mainly due to the
availability of ChIP-grade antibodies and previously published
ChIP-on-Chip data set [33]. Consistent with the findings of
Squazzo et al. [34], the PRC2 complex binds a different set of
genes in somatic cells compared to ES cells (Figure 5A right panel).
In addition, H3K27Me3 marks and SUZ12 binding in RL cells
did not overlap significantly with MRIs (Figure 5A), indicating that
H3K27Me3 may suppress the expression of a number of genes
without involving DNA methylation. This is consistent with a
previous study in solid tumor cell lines [35] and could be caused by
the switching of polycomb repressive marks between normal and
neoplastic cells [36].
In summary, we have developed a simple method for genome-
wide bisulfite sequencing analysis of methylation-enriched DNA.
The experimental protocols and the associated bioinformatic
software can be used for analyzing clinical samples. Using this
novel method, we conducted genome-wide mapping of combined
DNA methylation, H3K27Me3 and H3K4Me3 marks in
lymphoma cells to get an even more detailed insight for epigenetic
regulation in FL tumor cells. With dramatically increased interest
and coordinated community based efforts to decode the human
epigenome, a comprehensive picture of functional groups that
define gene expression patterns in normal and malignant cells is
emerging. The hierarchy of epigenetic regulation as described here
might facilitate an overall understanding of coordinated regulation
of gene expression in cancer and facilitated identification
biomarkers for earlier diagnosis, and molecular targets for cancer
therapy.
Methods
Tissue samples and cell cultures
Anonymous tumor and normal tissues were obtained from the
tissue bank established at Ellis Fischel Cancer Center, Columbia,
MO. 14 FL, 3 DLBCL, 2 FH and 2 whole blood samples were
used in this study. Histopathological classifications were according
to the guidelines of the World Health Organization (WHO). The
study was reviewed and approved by the Health Sciences
Institutional Review Board of the University of Missouri. PBMCs
were isolated using ficoll gradient centrifugation. CD19+ B-cells
were isolated with magnetic DynabeadsTM (Invitrogen, Carlsbad,
CA). The FL cell line, RL, was purchased from ATCC (Catalog
No. CRL-2261) and maintained in RPMI 1640 supplemented
with 10% FBS [31]. Gene reactivation experiments with DAC,
and TSA were described previously [10]. DNA and RNA were
isolated using the QIAmp DNA Blood Mini kit and RNeasy kits
respectively (Qiagen, Valencia, CA).
Preparation of linker ligated genomic DNA library
Genomic DNA (2 mg each) was digested to completion by
overnight incubation with Mse I, Bfa I, and Csp 6I (New England
Biolabs, Ipswich, MA), respectively (See Figure 1B left panel). The
digested fragments share a common feature; a TA overhang is
present at both ends of each fragment. Therefore these fragments
can be ligated to the same adapter. DNA was purified and Mse I,
Bfa I, and Csp 6I fragments mixed in equal proportions were
pooled together, and then ligated to adapter pre-annealed from
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oligonucleotides 59-AGTTATTCTGGACTGTCGAA GCTGA-
ATGCCATGG-39 and 59- pTACCATGGCATTCAGCTTC-
GACAGTCCAGAAT-39 in 50 ml volume containing 1600 U
T4 DNA ligase (New England Biolabs, Ipswich, MA) for 16 hr at
14uC. Excess adapters were removed using an ultrafiltration
column (Millipore, Billerica, MA).
MIRA
For enrichment of methylated CGIs, MIRA was performed as
described previously [37,38]. Four MIRA binding reactions were
performed with 500 ng of each adaptor-ligated genomic DNA
samples and incubated with MDB2b and MBD3L1 complexes
overnight at 4uC on a rocking platform. After washing the
pelletted Sepharose beads three times with binding buffer
containing 700 mM NaCl, the methylated DNA–enriched geno-
mic DNA fraction was eluted by addition of guanidinium
hydrochloride–containing buffer and purified using QIAquick
PCR purification kits according to the instructions of the
manufacturer (QIAGEN, Valencia, CA).
Bisulfite-PCR amplification
The captured DNA (40 ng) from MIRA experiments were
treated with bisulfite using the EZ Gold DNA methylation kit
(Zymo Research, Orange, CA) and eluted in 10 ml of water. The
bisulfite treated DNA was then amplified using forward primer (59-
TTGGATTGTTGAAGTTG AATG-39), and reverse primer (59-
AAACTATCAAAACTAAATACCATAATA-39). These primers
were designed to match the bisulfite converted linker primer
sequences used in the ligation step [39]. The PCR reaction was
performed in 50 ml volume, each containing 5 ml bisulfite-treated
DNA, 25 pmol of each PCR primer and 2.5 U PfuTurboCx
Hotstart DNA polymerase (Stratagene, La Jolla, CA). Touchdown
PCR was performed at annealing temperatures from 55 to 52uC
(two cycles at each temperature) followed by 10 cycles at an
annealing temperature of 51uC. Denaturation (94uC), annealing
and extension (72uC) times were 10 s, 30 s and 3 min,
respectively. The PCR products were purified with QIAquick
columns and amplified again for 10 cycles using an annealing
temperature of 55uC. The size of linker-PCR products ranges
from 200 bp to 800 bp with an average of 300 bp (Figure 1B right
panel). The PCR product was purified using AMPure beads
(Agencourt, Beverly, MA) to remove sub-quality fragments
(,200 bp) and then used for 454-sequencing.
Sequencing using 454-GS-FLX
The purified PCR products were end-repaired and ligated to
the sequencing adaptors using 454 library construction kits and
sequenced according to the manufacturer protocols (454 Life
Sciences, Branford, CT).
Methylation validation
Validation was performed for selected genes using MassAR-
RAYH EpiTYPER (Sequenom, San Diego, CA) on bisulfite-
converted DNA according to the manufacturer’s standard
protocols. The COBRA analysis was conducted as described
previously [31].
Expression microarrays
Illumina Sentrix 6 microarrays (Illumina, San Diego, CA) were
used for gene expression analysis. Labeling and hybridization were
carried out according the manufacturer’s standard protocols. Gene
expression data was analyzed using BeadStudio (Illumina, San
Diego, CA). Functional annotation and analysis were conducted
using Database for Annotation, Visualization and Integrated
Discovery (DAVID) v6.7 [40].
ChIP and ChIP-on-Chip
ChIP experiments were carried out using a Magna ChIP kit
(Millipore, Billerica, MA) following the manufacturer’s suggested
protocols. For each ChIP experiment, 56106 RL cells were
crosslinked with 10% formaldehyde at 37uC for 10 minutes. The
following antibodies were used: anti-trimethyl-H3K27 (Upstate,
no. 07-449), anti-trimethyl-H3K4 (Upstate, no. 04-745), and anti-
SUZ12 (Abcam, ab-12073). For hybridization to the microarrays,
10 ng each of Input and ChIP DNA samples was amplified using
GenomePlex WGA kit (Sigma-Aldrich, St. Louis, MO). The Input
and ChIP samples were labeled with Cy3 and Cy5 fluorescent dye
and co-hybridized on to the NimbleGen promoter microarray
(Roche-NimbleGen, Madison, WI) according to manufacturer
protocols. The array data were extracted according to standard
operating procedures by NimbleGen Systems Inc. The peaks were
identified with a cut-off of false discovery rate (FDR) of ,0.05
using NimbleGen SignalMap software. The NimbleGen GFF files
were then converted into Wiggle format and uploaded to the
UCSC Genome Browser for visualization.
Sequencing data analysis
The sequence reads were mapped to the human genome by an
in-house mapping program, called BSmapper (http://sourceforge.
net/projects/bsmapper), using suffix array and bit-parallelism,
leveraging our previous work on genome assembly and genome
alignment algorithms [41]. We divided a mapping process into two
phases to model possible bisulfite conversion, i.e., C to T and G to
A. For each phase, we converted Ts (As) to Cs (Gs) in reads and
reference sequences. A suffix array was built to index the
converted reference sequence. We searched the suffix array for a
seed (word) of a converted read. We filtered the seed if it contained
unallowed cases, i.e., matching T (A) to C (G) from the reference
sequence to the seed. Given a set of seeds, we merged seeds if they
were near in both reference genome and read. Finally, we aligned
flanking regions of seeds and chose the best alignment. BSmapper
can be compiled and run in various UNIX environments including
MAC OS X and Cygwin for MS-Windows. Pairwise alignments
between sequence reads and the reference genome were used for
generating clusters with multiple sequence alignments using
BioPerl. We built custom tracks of the alignment results that can
be uploaded to the UCSC genome browser. The MRIs were
compared with UCSC genes, RefSeq genes, CpG islands, and
RepeatMasked regions. The corresponding data can be accessed
at http://people.cgb.indiana.edu/jeochoi/methylation. By click-
ing on the names of the read in UCSC genome browser, one can
download the sequence from the ‘‘External Link’’ that is linked to
our bisulfite-sequence database. All the sequences aligned to the
same cluster were visualized using a multiple sequence alignment
program. The methylated and unmethylated CpGs were high-
lighted using different colors. Bisulfite conversion rate was
calculated as the number of genomic cytosines outside a CpG
context that were unconverted, divided by the total number of
cytosines outside a CpG context.
Determination of the methylation index for each cluster
We defined a cluster as a region that was mapped with more
than 5 overlapping or continuous reads. To calculate the
methylation index of a cluster, the methylation status of each
CpG site in each sequence read was first determined based on a C
to T conversion at each CpG site on the forward strand and a G to
A conversion on the reverse strand. The percentage of methylation
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at each CpG site within each cluster was calculated based on the
number of sequences containing methylated CpG sites versus the
total number of sequences analyzed. Finally, the methylation index
for each cluster was calculated by averaging the methylation levels
of all CpGs within each cluster. The methylation statuses of
nearby CpGs are usually correlated; particularly in this case,
where the clusters were identified through specific capture of
methylated DNA. Therefore, it is reasonable to group the nearby
CpGs and calculate the average methylation levels. The
methylation indices allowed us to identify those regions that are
significantly methylated and eliminate the false positives.
Data access
The raw sequencing data has been submitted to NCBI sequence
read archive website (http://trace.ncbi.nlm.nih.gov/Traces/sra_
sub/) and the accession number is SRA010812.4. The NimbleGen
microarray data from this study have been submitted to the NCBI
gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo)
under accession no. GSE20019. The bisulfite sequence tracks in
UCSC genome browser format are available on our website
(http://people.cgb.indiana.edu/jeochoi/methylation.) The source
code package with documentation is available online at http://
sourceforge.net/projects/bsmapper.
Supporting Information
Figure S1 Distribution of MRIs in the genomes of RL and
CD19+ B-cells. Figure was generated using the Genome Graphs, a
built-in function of the UCSC genome browser. Each dot indicates
a MRI as defined in the main text. Blue: RL; Red: CD19+ B-cells.
The light green area indicates genomic regions where no MRI was
identified in either sample. The Y-axis indicates the methylation
indices (a value of 0 to 1) of each MRI.
Found at: doi:10.1371/journal.pone.0013020.s001 (3.20 MB TIF)
Figure S2 Sequenom MassArray analyses validating the 454
sequencing results of four representative genes, A-D. For each
gene, the top panel shows the 454 bisulfite sequencing results. The
description of the track is same as described in the paper. The
bottom panel shows the results obtained from the MassArray
analysis. Bisulfite- treated genomic DNA from normal PBMC,
CD19 B-cell, a FL patient sample and RL cells was used as the
template for PCR. Each circle indicates a CpG site and the
methylation level is indicated by color. Four technical replicates
were analyzed for the each sample.
Found at: doi:10.1371/journal.pone.0013020.s002 (5.84 MB TIF)
Figure S3 Results from a permutation test which examines
whether the distribution of methylation levels of clusters was
obtained by chance. A. Average methylation levels of clusters in
1000 permutation. The Y-axis represents the average number of
MRIs for a bin of methylation levels and the error bars represent
standard deviation. B. Histogram of p-values in 1000 permutation.
The p-values were calculated by a student t-test between the
original and permutated distributions. C. Histogram of MRIs in
1000 permutation. After discarding clusters of equal or less than
20% methylation, MRIs were determined in each permutation.
The minimum, mean, and maximum numbers of MRIs are
12,369, 12,684, and 12,715. The distribution was far from 11,971
and demonstrated that the distribution was not obtained by
chance.
Found at: doi:10.1371/journal.pone.0013020.s003 (2.05 MB TIF)
Figure S4 Comparison of the methylation levels of overlapping
CpG sites between RL and CD19+ B-cells. A Pearson correlation
coefficient of 0.33 was observed between the two samples,
suggesting significantly differential methylation.
Found at: doi:10.1371/journal.pone.0013020.s004 (0.66 MB TIF)
Figure S5 DNA methylation and histone modification profiles of
4 Hox gene clusters in RL cells. Each blue bar corresponds to the
log2 ratio of ChIP/Input DNA for an individual probes. The
methylation tracks are the same as described in the paper.
Found at: doi:10.1371/journal.pone.0013020.s005 (1.65 MB TIF)
Figure S6 Bisulfite sequencing results of protocadherin gene
clusters. A. Alignment results of bisulfite sequencing reads in the
PCDHGA-B gene clusters. B. Alignment results of bisulfite
sequencing reads in the PCDHA gene clusters. Custom tracks
were uploaded into the UCSC genome browser. The vertical line
in red color indicates the level of methylation at each CpG site.
The deeper red shade indicates the higher methylation level. The
blue color peaks show the sequencing coverage for each cluster.
Found at: doi:10.1371/journal.pone.0013020.s006 (3.26 MB TIF)
Figure S7 Functional analysis of genes associated with MRIs in
the 59-end. Enrichment scores from analysis of 1,817 annotated
genes hypermethylated in RL using DAVID (http://david.abcc.
ncifcrf.gov/). The x-axis shows the percentage of methylated genes
that fall into functional groups. y-axis shows the functional group.
The p-value represents the likelihood that a group of genes are
NOT enriched by chance.
Found at: doi:10.1371/journal.pone.0013020.s007 (0.14 MB TIF)
Figure S8 The HIC-1 gene, an example of bisulfite sequencing
alignment results. The custom track on the top panel shows the
methylation levels. Red color indicates the methylated CpGs. The
lower panel shows the externally linked multiple alignment results.
The methylated and unmethylated CpGs are also highlighted
using different colors.
Found at: doi:10.1371/journal.pone.0013020.s008 (0.53 MB
PDF)
Figure S9 The HLA-A gene, another example of bisulfite
sequencing alignment results. The custom track on the top panel
shows the methylation levels. Red color indicates the methylated
CpGs. The lower panel shows multiple alignment results. The
methylated and unmethylated CpGs are also highlighted using
different colors. A heterozygous polymorphism (rs41558424)
seems to correlate with the two unmethylated CpG sites that are
30 to 50 bp downstream of the SNP.
Found at: doi:10.1371/journal.pone.0013020.s009 (4.15 MB TIF)
Figure S10 Oncomine concepts map of methylated genes in RL
compared to the known polycomb target genes in ES cells. Node
represent molecular concepts (biologically related gene sets. Node
size is proportional to the number of genes in the concept. Each
edge represents a significant enrichment (p,0.05).
Found at: doi:10.1371/journal.pone.0013020.s010 (1.26 MB TIF)
Figure S11 Mapping of Suz12, H3K4Me3 and H3K27Me3 to
their target promoters. The NimbleGen promoter oligonucleotide
array was hybridized with amplicons prepared from ChIP
experiments using antibodies against SUZ12, H3K4Me3 and
H3K27Me3, and the input control. Shown are three promoter
regions: two that were repressed by SUZ12 (PAX7 and LHX5)
and one that is not repressed by SUZ12 and actively transcribed
(c-Jun). The fold enrichment was calculated by dividing the
SUZ12 or H3K4Me3 and H3K27Me3 hybridization intensity
signal by the input control signal for each oligonucleotide probe.
Each green bar corresponds to the log2 ratio of ChIP/Input DNA
for an individual probes. The inserts within each graph show
independent ChIP confirmation using PCR analysis. The primers
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used in the PCR analysis were designed to span the region (blue
horizontal bar) showing the highest peak of enrichment for each
promoter.
Found at: doi:10.1371/journal.pone.0013020.s011 (0.85 MB TIF)
Table S1 List of MRIs associated with gene promoters in RL
cells.
Found at: doi:10.1371/journal.pone.0013020.s012 (1.08 MB
XLS)
Table S2 List of MRIs associated with gene promoters in
CD19+ B-cells.
Found at: doi:10.1371/journal.pone.0013020.s013 (0.06 MB
XLS)
Table S3 List of genes marked by H3K4Me3 in the promoter
regions in RL cells.
Found at: doi:10.1371/journal.pone.0013020.s014 (1.33 MB
XLS)
Table S4 List of genes marked by H3K27Me3 in the promoter
regions in RL cells
Found at: doi:10.1371/journal.pone.0013020.s015 (0.57 MB
XLS)
Table S5 List of SUZ12 target genes in RL cells
Found at: doi:10.1371/journal.pone.0013020.s016 (0.17 MB
XLS)
Table S6 p value of pair wise t-test results. The gene expression
data in each column of the three panels in Figure 6A was used to
conduct the test.
Found at: doi:10.1371/journal.pone.0013020.s017 (0.03 MB
XLS)
Acknowledgments
We thank Drs. Tim Huang, Kenneth Nephew and Phillip Buckhaults for
critical review of this manuscript.
Author Contributions
Conceived and designed the experiments: CC HS. Performed the
experiments: YL JG LP TAR SM GW LBB JLS KHT HS. Analyzed
the data: JHC RSK SK DX HS. Contributed reagents/materials/analysis
tools: AS GPP BAR KB. Wrote the paper: JHC KHT DX CC HS.
References
1. Robertson KD (2005) DNA methylation and human disease. Nat RevGenet 6:
597–610.
2. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer.
NatRevGenet 3: 415–428.
3. Laird PW (2003) The power and the promise of DNA methylation markers.
NatRevCancer 3: 253–266.
4. Shi H, Wang MX, Caldwell CW (2007) CpG islands: their potential as
biomarkers for cancer. Expert Rev Mol Diagn 7: 519–531.
5. Issa JP (2007) DNA methylation as a therapeutic target in cancer. ClinCancer
Res 13: 1634–1637.
6. Killian JK, Bilke S, Davis S, Walker RL, Killian MS, et al. (2009) Large-scale
profiling of archival lymph nodes reveals pervasive remodeling of the follicular
lymphoma methylome. Cancer research 69: 758–764.
7. Martin-Subero JI, Ammerpohl O, Bibikova M, Wickham-Garcia E, Agirre X,
et al. (2009) A comprehensive microarray-based DNA methylation study of 367
hematological neoplasms. PLoS ONE 4: e6986.
8. O’Riain C, O’Shea DM, Yang Y, Le Dieu R, Gribben JG, et al. (2009) Array-
based DNA methylation profiling in follicular lymphoma. Leukemia 23:
1858–1866.
9. Rahmatpanah FB, Carstens S, Guo J, Sjahputera O, Taylor KH, et al. (2006)
Differential DNA methylation patterns of small B-cell lymphoma subclasses with
different clinical behavior. Leukemia 20: 1855–1862.
10. Bennett LB, Schnabel JL, Kelchen JM, Taylor KH, Guo J, et al. (2009) DNA
hypermethylation accompanied by transcriptional repression in follicular
lymphoma. Genes, chromosomes & cancer 48: 828–841.
11. Schwartz YB, Pirrotta V (2008) Polycomb complexes and epigenetic states. Curr
Opin Cell Biol 20: 266–273.
12. Schuettengruber B, Chourrout D, Vervoort M, Leblanc B, Cavalli G (2007)
Genome Regulation by Polycomb and Trithorax Proteins. Cell 128: 735–745.
13. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, et al. (2005) The Polycomb
group protein EZH2 directly controls DNA methylation. Nature 439: 871–874.
14. Su Ih, Basavaraj A, Krutchinsky AN, Hobert O, Ullrich A, et al. (2003) Ezh2
controls B cell development through histone H3 methylation and Igh
rearrangement. Nat Immunol 4: 124–131.
15. van Kemenade FJ, Raaphorst FM, Blokzijl T, Fieret E, Hamer KM, et al. (2001)
Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with
cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood
97: 3896–3901.
16. Raaphorst FM (2005) Deregulated expression of Polycomb-group oncogenes in
human malignant lymphomas and epithelial tumors. Hum Mol Genet 14:
R93–100.
17. Mikkelsen TS, Ku M, Jaffe DB, Issac B, Lieberman E, et al. (2007) Genome-
wide maps of chromatin state in pluripotent and lineage-committed cells. Nature
448: 553–560.
18. Rauch TA, Wu X, Zhong X, Riggs AD, Pfeifer GP (2009) A human B cell
methylome at 100-base pair resolution. Proceedings of the National Academy of
Sciences of the United States of America 106: 671–678.
19. Mayor R, Casadome L, Azuara D, Moreno V, Clark SJ, et al. (2009) Long-range
epigenetic silencing at 2q14.2 affects most human colorectal cancers and may
have application as a non-invasive biomarker of disease. Br J Cancer 100:
1534–1539.
20. Coolen MW, Stirzaker C, Song JZ, Statham AL, Kassir Z, et al. Consolidation
of the cancer genome into domains of repressive chromatin by long-range
epigenetic silencing (LRES) reduces transcriptional plasticity. Nat Cell Biol 12:
235–246.
21. Taylor KH, Kramer RS, Davis JW, Guo J, Duff DJ, et al. (2007) Ultradeep
Bisulfite Sequencing Analysis of DNA Methylation Patterns in Multiple Gene
Promoters by 454 Sequencing. Cancer Research 67: 8511–8518.
22. Cokus SJ, Feng S, Zhang X, Chen Z, Merriman B, et al. (2008) Shotgun
bisulphite sequencing of the Arabidopsis genome reveals DNA methylation
patterning. Nature 452: 215–219.
23. Lister R, O’Malley RC, Tonti-Filippini J, Gregory BD, Berry CC, et al. (2008)
Highly integrated single-base resolution maps of the epigenome in Arabidopsis.
Cell 133: 523–536.
24. Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, et al. (2009) Human
DNA methylomes at base resolution show widespread epigenomic differences.
Nature 462: 315–322.
25. Meissner A, Mikkelsen TS, Gu H, Wernig M, Hanna J, et al. (2008) Genome-
scale DNA methylation maps of pluripotent and differentiated cells. Nature 454:
766–770.
26. Zeschnigk M, Martin M, Betzl G, Kalbe A, Sirsch C, et al. (2009) Massive
parallel bisulfite sequencing of CG-rich DNA fragments reveals that methylation
of many X-chromosomal CpG islands in female blood DNA is incomplete. Hum
Mol Genet 18: 1439–1448.
27. Ball MP, Li JB, Gao Y, Lee JH, LeProust EM, et al. (2009) Targeted and
genome-scale strategies reveal gene-body methylation signatures in human cells.
Nat Biotechnol 27: 361–368.
28. Deng J, Shoemaker R, Xie B, Gore A, LeProust EM, et al. (2009) Targeted
bisulfite sequencing reveals changes in DNA methylation associated with nuclear
reprogramming. Nat Biotechnol 27: 353–360.
29. Hodges E, Smith AD, Kendall J, Xuan Z, Ravi K, et al. (2009) High definition
profiling of mammalian DNA methylation by array capture and single molecule
bisulfite sequencing. Genome Res 19: 1593–1605.
30. Gu H, Bock C, Mikkelsen TS, Jager N, Smith ZD, et al. Genome-scale DNA
methylation mapping of clinical samples at single-nucleotide resolution. Nature
Methods 7: 133–136.
31. Shi H, Guo J, Duff DJ, Rahmatpanah F, Chitima-Matsiga R, et al. (2007)
Discovery of novel epigenetic markers in non-Hodgkin’s lymphoma. Carcino-
genesis 28: 60–70.
32. Saito M, Gao J, Basso K, Kitagawa Y, Smith PM, et al. (2007) A signaling
pathway mediating downregulation of BCL6 in germinal center B cells is
blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell 12: 280–292.
33. Mikkelsen T, Ku M, Jaffe D, Issac B, Lieberman E, et al. (2007) Genome-wide
maps of chromatin state in pluripotent and lineage-committed cells. Nature 448:
553 - 560.
34. Squazzo SL, O’Geen H, Komashko VM, Krig SR, Jin VX, et al. (2006) Suz12
binds to silenced regions of the genome in a cell-type-specific manner. Genome
Res 16: 890–900.
35. Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, et al. (2008) Gene
silencing in cancer by histone H3 lysine 27 trimethylation independent of
promoter DNA methylation. Nature genetics 40: 741–750.
36. Gal-Yam EN, Egger G, Iniguez L, Holster H, Einarsson S, et al. (2008) Frequent
switching of Polycomb repressive marks and DNA hypermethylation in the PC3
MIRA Bisulfite Sequencing
PLoS ONE | www.plosone.org 14 September 2010 | Volume 5 | Issue 9 | e13020
prostate cancer cell line. Proceedings of the National Academy of Sciences of the
United States of America 105: 12979–12984.
37. Rauch T, Li H, Wu X, Pfeifer GP (2006) MIRA-Assisted Microarray Analysis, a
New Technology for the Determination of DNA Methylation Patterns, Identifies
Frequent Methylation of Homeodomain-Containing Genes in Lung Cancer
Cells. Cancer Research 66: 7939–7947.
38. Rauch T, Wang Z, Zhang X, Zhong X, Wu X, et al. (2007) Homeobox gene
methylation in lung cancer studied by genome-wide analysis with a microarray-
based methylated CpG island recovery assay. Proceedings of the National
Academy of Sciences 104: 5527–5532.
39. Meissner A, Gnirke A, Bell GW, Ramsahoye B, Lander ES, et al. (2005)
Reduced representation bisulfite sequencing for comparative high-resolution
DNA methylation analysis. Nucleic Acids Res 33: 5868–5877.
40. Huang DW, Sherman BT, Lempicki RA (2008) Systematic and integrative
analysis of large gene lists using DAVID bioinformatics resources. Nat Protocols
4: 44–57.
41. Choi JH, Cho HG, Kim S (2005) GAME: a simple and efficient whole genome
alignment method using maximal exact match filtering. Comput Biol Chem 29:
244–253.
42. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, et al. (2000) Distinct types
of diffuse large B-cell lymphoma identified by gene expression profiling. Nature
403: 503–511.
MIRA Bisulfite Sequencing
PLoS ONE | www.plosone.org 15 September 2010 | Volume 5 | Issue 9 | e13020
